DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug for rare Skin-Lung disease fails to reach goal
Disease control TerminatedThis study tested an experimental drug called HZN-825 in about 300 people with a rare autoimmune disease that causes skin thickening and can harm the lungs. The trial was stopped early, so results are not available. Participants took the drug or a placebo daily for up to 52 weeks…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 17, 2026 05:08 UTC
-
Promising scleroderma drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called HZN-825 in people with a severe form of scleroderma that affects the skin and lungs. The trial was stopped early, but researchers measured changes in lung function and tracked side effects over 52 weeks. Participants had already compl…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 14, 2026 12:06 UTC